Nuzenio

Vipivotide Tetraxetan

Vipivotide Tetraxetan news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 17 latest news signals 17 publisher sources 100/100 entity strength

Latest news

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT Dr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - OncLiveOncLive · Thu, 06 Aug 2026 16:51:58 GMT FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 10:28:25 GMT FDA Approves Pluvicto for Earlier Use in Prostate Cancer - SurvivorNetSurvivorNet · Tue, 04 Aug 2026 17:34:02 GMT FDA Approves Pluvicto for Early-Stage Metastatic Prostate Cancer - WebMDWebMD · Mon, 03 Aug 2026 23:11:02 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Mon, 03 Aug 2026 17:37:08 GMT Pluvicto Approved Earlier in Metastatic Prostate Cancer - MedscapeMedscape · Mon, 03 Aug 2026 14:03:57 GMT FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for Prostate Cancer - Oncology News CentralOncology News Central · Mon, 03 Aug 2026 10:27:38 GMT

Timeline

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Thu, 06 Aug 2026 16:51:58 GMTDr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - OncLive

Wed, 05 Aug 2026 10:28:25 GMTFDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - Oncodaily

Tue, 04 Aug 2026 17:34:02 GMTFDA Approves Pluvicto for Earlier Use in Prostate Cancer - SurvivorNet

Mon, 03 Aug 2026 23:11:02 GMTFDA Approves Pluvicto for Early-Stage Metastatic Prostate Cancer - WebMD

Mon, 03 Aug 2026 17:37:08 GMTFDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

Pluvicto15 live mentions PSMA12 live mentions S Prostate Cancer8 live mentions FDA6 live mentions ARPI6 live mentions Positive4 live mentions FDA Approves Pluvicto4 live mentions FDA Approves Lutetium4 live mentions Metastatic Prostate Cancer4 live mentions Vipivotide Tetraxetan Plus4 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Vipivotide Tetraxetan.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

17 distinct publisher/source names are currently connected to this entity page.